Movie Casting Call
Author:
Kestrel Therapeutics Inc.
Kestrel Therapeutics Announces IND Clearance by U.S. FDA of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, Enabling Initiation of Phase 1 Trial
March 5, 2026